*EMBARGOED All research presented at the ACG Annual Scientific Meeting is strictly embargoed until Monday, October 17, 2016 at 8:00 am EDT.
Poster 1823 Assessment of Sponge-on-String Device Parameters for the Non-endoscopic Detection of Barrett’s esophagus: Results from a Randomized Trial
Author Insight from Prasad G. Iyer, MD, MSc, FACG, Mayo Clinic
What’s new here and important for clinicians?
This abstract details our efforts to develop a minimally invasive method of screening for Barrett’s esophagus (BE) using a capsule sponge combined with novel methylated DNA markers. In this randomized controlled trial, we compared the tolerability and safety of two types of sponges (a 25 mm/10 pores per inch versus a 25 mm/20 pores per inch) in patients with and without BE. The capsules were successfully swallowed by 98% of participants. Patient tolerability was better with the 25/10 pores-per-inch sponge. Additionally, the capsule sponge did not cause any significant trauma in the esophagus and was safe.
Finally a two DNA methylated marker panel was able to accurately classify the presence or absence of BE with 100% accuracy, making this a promising test for BE screening.
What do patients need to know?
This is a potentially exciting screening tool for Barrett’s esophagus and esophageal cancer.
Prasad G. Iyer, MD, MSc, FACG, Mayo Clinic
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at email@example.com or by phone at 301-263-9000.